Accelera
Accelera is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma
Sponsor Nerviano Medical Sciences S.r.l.
- Start (EU)
- Latest update
- Estimated end
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML
Sponsor Nerviano Medical Sciences S.r.l.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Accelera?
The 2026-10-09 snapshot links Accelera to 2 distinct CTIS trials. Recorded services include PK Analysis, Primary/ surrogate endpoint test. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Accelera?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Accelera conducted?
The linked trials record locations in 4 countries, including Italy, Spain, France, Netherlands. These are trial locations, not confirmed office locations or countries where Accelera delivered services.
What can this page tell me about Accelera's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Accelera. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Accelera S.r.l.